Rationale: Calmodulin (CaM) associates with cardiac ryanodine receptor type-2 (RyR2) as an important regulator.
A pproximately 50% of heart failure (HF) patients die of ventricular arrhythmia and sudden cardiac death. 1 It is known that ryanodine receptor type-2 (RyR2)-mediated Ca 2+ leak from the sarcoplasmic reticulum (SR) during diastole can activate inward current via Na/Ca exchange 2 and evoke delayed afterdepolarizations. In HF, there is enhanced diastolic SR Ca 2+ leak via RyR2 and other electrophysiological changes that greatly enhance the propensity for delayed afterdepolarizations and triggered cardiac arrhythmias, a leading cause of ventricular tachyarrhythmia and sudden cardiac death. [3] [4] [5] [6] Thus, RyR2 has emerged as a potential therapeutic target for treating HF and arrhythmia. Stabilizing RyR2 and preventing abnormal Ca 2+ leak (without affecting normal excitation-contraction coupling) may be a valid therapeutic approach.
Calmodulin (CaM) is an important RyR2 regulator, but has multiple cellular targets. CaM has 2 pairs of globular Ca
2+
-binding E-F hand domains connected by a flexible linker. 7 At high [Ca] 2+ , Ca 2+ binds cooperatively to CaM, inducing a conformational change that translates intracellular [Ca] 2+ signals to diverse processes via many targets, including myosin light chain kinase, calcineurin, nitric oxide synthase, phosphodiesterase, adenylyl cyclase, Ca 2+ /CaM-dependent kinase (CaMK), Ca 2+ -activated potassium channels, l-type Ca 2+ channels (LTCCs), and RyRs. [8] [9] [10] [11] CaM binds to RyR2 stoichiometrically (4 CaMs per tetrameric RyR2), and amino acids 3583 to 3603 on RyR2 are essential for this interaction. [12] [13] [14] CaM inhibits RyR2 opening at all [Ca] 2+ and, as such, may be a critical regulator of SR Ca 2+ release. 13, 14 Cryo-EM-based 3-dimensional reconstruction studies showed that Ca 2+ -free CaM (apoCaM) binds in the RyR cytosolic domain 3, within 60Å to 70Å from FK506-binding protein 12.6 (FKBP12.6) bound on the same RyR face, and we have demonstrated that fluorescence resonance energy transfer (FRET) can be measured between these partners bound to either RyR1 or RyR2. 17, 18 FKBP12.6 was reported to bind RyR2 tightly as an important regulator in RyR2 gating, but aspects of the FKBP12.6-RyR2 interaction and function remain controversial. [19] [20] [21] [22] It was also reported that CaM could stabilize RyR2 in the closed state during diastole and facilitate the termination of Ca 2+ release by decreasing the probability of channel reopening and prolonging the closed time. 23 Defective CaM-RyR2 interaction has potentially broad implication in cardiac pathology. Mutations of critical residues in the highly conserved CaM-binding region can severely decrease or abolish CaM binding to RyR2 and cause severe hypertrophic cardiomyopathy and early death in animals. 13, 24 In nonischemic HF animal models, CaM binding to RyR2 was decreased. 25, 26 A recent study indicates that defective CaM binding to RyR2 is also involved in catecholaminergic polymorphic ventricular tachycardia (CPVT)-associated RyR2 dysfunction. 27 So, the CaM-RyR2 interaction may be critical for arrhythmias and HF pathogenesis.
Here, we used FRET to resolve RyR-bound CaM from other CaM targets and, in the native myocyte environment, to characterize CaM-RyR2 interaction properties for normal and HF cardiomyocytes. Knock-in (KI) heterozygous mice (RyR2 ADA/+ ), 13 with genetically disrupted CaM-RyR2 association (W3587A/L3591D/F3603A, denoted ADA), were used to estimate what percentage of Z-line-bound CaM is RyR2-bound and to test for increased arrhythmia susceptibility in both myocytes and intact animals under acute stress. This would be analogous to what is seen in CPVT, which is linked to RyR2 mutations. 28, 29 This ADA mutant RyR2 is not expected to change CaM effects at other CaM targets. Human mutations in CaM have recently been associated with CPVT, which may be partially recapitulated by these RyR2 ADA/+ mice.
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Methods
Ventricular myocytes were isolated as previous described 22 
Results
Steady-State Binding of CaM to RyR2
Predepletion of Endogenous CaM by Suramin
RyR2s are concentrated at Z-lines, which is also true for CaM, 34 and ≈90% of apoCaM-binding sites are occupied by endogenous CaM. 34 Online Figure IAi shows the F-CaM Z-line striation pattern after 60 nmol/L F-CaM was washed in. Suramin (5 μmol/L) wash-in abolished striations within 60 s (Online Figure IAii) , indicating F-CaM dissociation from Z-line sites. After suramin-dependent stripping and subsequent wash-out (20 minutes), F-CaM rebound at Z-lines, restoring striations (Online Figure IAiii) . Before suramin treatment, F-CaMbinding kinetics was slow (time constant, τ =11.5 minutes; Online Figure IB ), which represents F-CaM replacing endogenous RyR-bound CaM. 34 After depleting endogenous RyRbound CaM with suramin, F-CaM binding was much faster (τ=2 minutes; Online Figure IC) , reflecting F-CaM binding to unoccupied binding sites. Binding maximum (B max ) was not significantly altered by suramin pretreatment, indicating that suramin completely depleted endogenous Z-line-bound CaM and that CaM and suramin binding are completely reversible.
Steady-State CaM-RyR2 Binding Affinity
Strong FRET between F-FKBP and F-CaM is effective in distinguishing CaM bound to RyR2 versus other CaM targets. 18 After suramin pretreatment, 100 nmol/L F-FKBP (donor) was washed in to saturate FKBP-binding sites on RyR2. 18, 22 Then, different F-CaM (acceptor) concentrations were washed in and allowed to reach steady state (20-120 minutes). RyR2-bound CaM is detected through FRET by sensitized emission. Figure To test whether FRET occurs between 1 donor and 1 acceptor, in Figure 1C we plotted donor signal (y axis) versus acceptor signal (x axis) for the same [F-CaM] , from experiments shown in Figure 1B . The dependence of donor fluorescence (F-FKBP; decreasing because of FRET) on acceptor fluorescence (F-CaM; increasing FRET) is linear, consistent with bimolecular FRET. 35 This suggests that FRET is exclusively CaM at the Z-lines (B max ; Figure 1E ) is 1.2 μmol/L, similar to our previous results 36 and consistent with the B max for FKBP12.6 in rat myocytes.
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Kinetics of CaM Binding to RyR2
FRET-Based Measurement of k on and k off During Wash-In and Wash-Out in Myocytes After CaM depletion, permeabilized myocytes were saturated with F-FKBP (100 nmol/L). Using FRET, we characterized CaM-RyR2 association (k on ) and dissociation (k off ) rate constants in F-CaM wash-in/out experiments ( Figure 2A ). During wash-out, fluorescent striations gradually dissipated along a single exponential decay (τ=4.5 minutes), which corresponds to k off =0.22±0.01/min (n=5). For wash-in, CaMRyR2 association rate is a function of k on , k off , and [F-CaM] (k wash-in =k on [CaM]+k off ). Using the k off and the wash-in data, we calculated k on =18.9±1.6×10 Percentage of Total Z-Line CaM That Is RyR2-Bound KI mice with genetically disrupted CaM-RyR2 interaction are used here (along with WT mice) to estimate the percentage of total Z-line-bound CaM that is RyR2-bound. These KI mice express RyR2 with a triple mutation (RyR2-W3587A/ L3591D/F3603A, RyR2 ADA/+ ) that prevents high-affinity binding of CaM. 13 Homozygous (RyR2
) mice all die within 16 days of birth with a severe HF phenotype, loss of T-tubule/junctional couplings, and ≈70% decrease in RyR2 expression, making them unsuitable here. 13, 24 However, the heterozygous mice (RyR2 structural defects and exhibit normal lifespan and RyR2 expression levels. 13 We find that RyR ADA/+ myocytes exhibit reduced F-CaM binding both to the RyR2 (by FRET) and at the Z-line (by direct F-CaM excitation; Figure 3A and 3B). For RyR2 ADA/+ , there is a 50±2% reduction in FRET at saturating [F-CaM] (FRET max ), with no significant change in K d ( Figure 3C ). This fits the expectation that in RyR2 ADA/+ mice ≈50% of the RyR2 monomers have the triple mutation and defective CaM binding. There is also a 46±2% reduction of total CaM at the Z-line ( Figure 3D ), which is primarily because of the 50% decrease in CaM binding to RyR2. This suggests that ≈92% of Z-line-localized CaM is bound to RyR2. We also measured RyR2 monomer expression as total binding (B max ) of FKBP12.6 (Online Figure III) (Figure 2A) , we modified the permeabilization protocol for Ca 2+ spark measurements to limit this disadvantage. For Ca 2+ spark measurements, myocytes were exposed to saponin (50 μg/mL) for only 20 to 30 s instead of 3 minutes as used above for CaM wash-in. Online Figure IV shows that after 20 to 30 s of permeabilization Ca 2+ sparks were readily detected in myocytes after 20-minute exposure to F-FKBP, F-CaM, and fluo-4. However, there was no visible striated pattern observable for F-FKBP, F-CaM, or FRET. This indicates that fluo-4 can enter the cell with this gentler permeabilization, but proteins (eg, CaM and FKBP12.6) cannot. With the 3-minute permeabilization protocol, both FRET striation pattern and Ca 2+ sparks were detected, indicating that all 3 probes entered the cell. This shows that 20-to 30-s permeabilization can also effectively limit FKBP12.6 and CaM wash-out during the time of Ca 2+ spark measurement. Thus, we can undertake Ca 2+ spark measurement in the relatively native cellular environment with respect to CaM and FKBP12.6 concentrations. Figure 4B ). Ca 2+ spark frequency depends steeply on SR Ca 2+ content, 37 such that the new steady-state spark frequency underestimates the magnitude of the primary effect. The increased Ca 2+ spark frequency could not be prevented by the specific CaMKII inhibitor autocamtide-2-related inhibitory peptide, AIP ( Figure 4B ), ruling out a contribution of CaMKII. These results are consistent with half of the RyR2 monomers lacking CaM, allowing higher RyR2 activity.
In a second series of spark experiments, we compared the effect of endogenous CaM (as above) with CaM wash-out and readmission in WT and RyR2
ADA/+ mice (Online Figure V) full width at half-maximum were already high (comparable to that in CaM-free WT myocytes) and were not influenced by CaM wash-out or readmission. Thus, even 500 nmol/L CaM cannot reverse the high Ca 2 spark frequency caused by defective CaM-RyR2 interaction (Online Figure V) .
We also increased intracellular [Ca] 2+ to 100 nmol/L, close to the threshold for Ca 2+ waves in WT mouse myocytes, to further test the propensity for delayed afterdepolarizations or arrhythmogenesis. The increased [Ca] 2+ mimics a Ca 2+ loading stress in permeabilized cells, because both cytosolic and SR Ca 2+ load are increased. In RyR2 ADA/+ mice, ≈90% of myocytes produced Ca 2+ waves versus only ≈10% of myocytes for WT mice ( Figure 4C and 4D ), again without a significant difference in Ca 2+ SR load ( Figure 4D ). The caffeine-induced Ca transients were induced during sweeps where no waves occurred, to limit underestimation of SR Ca 2+ content that would occur in the wake of a wave. These triggered events could reflect increased arrhythmogenic risk in RyR2 ADA/+ mice, analogous to CPVT.
Ventricular Arrhythmia in RyR2 ADA/+ KI Mouse To test whether the RyR2
ADA/+ KI mice are more susceptible to CPVT-like arrhythmias, we measured ECGs in intact mice during injection of ISO plus caffeine as has been performed in CPVT mouse models. 40 Figure 7A shows that RyR2
ADA/+ KI mice developed severe stress-inducible ventricular arrhythmia. All RyR2 ADA/+ mice exhibited sustained bigeminy (>20 minutes), a precursor for ventricular tachycardia (VT; Figure 7B ). In 60% of RyR2 ADA/+ mice, bidirectional VT was induced ( Figure 7B ), and episodes of VT were frequent (4.5 per mouse) in RyR2 ADA/+ mice. In contrast, none of the WT mice exhibited inducible arrhythmia in this protocol.
Binding Affinity of CaM/FKBP12.6 to RyR2 in HF Myocytes
We measured CaM-RyR2 affinity in a rat HF model induced by coronary ligation. Twelve weeks postinfarct, these rats exhibited increased heart/body weight ratio, increased left ventricular diastolic dimensions, and decreased fractional shortening. 31, 32 Other HF molecular markers (ANP, BNP, TNF-α) are also increased in this model. 32 The HF rats used here had reduced fractional shortening (<20% versus normal; 46%) and elevated left ventricular diastolic dimensions (Online Figure  VI) . We used FRET to measure the CaM-RyR2 affinity. In HF versus normal myocytes, the CaM-RyR2 affinity was ≈3-fold lower (K d =51±4 nmol/L; Figure 8A ). We also performed paired experiments with sham rats, with [F-CaM] near the K d and saturating (FRET max ; Figure 8B ). At [F-CaM] near WT K d , changes in affinity are readily detected, and binding was significantly lower in HF. FRET max was unaltered.
FKBP12.6 was suggested to also be a critical RyR2 stabilizer, with decreased affinity in HF (although this is controversial). 41 Using methods previously described, 22 we measured, for the first time within HF myocytes, the FKBP12.6-RyR2 affinity (K d =0.8±0.1 nmol/L; Figure 8C ). This is almost identical to the K d we previously measured in normal rat myocytes under the same conditions (0.7±0.1 nmol/L). 21 We also performed paired experiments (as for CaM). We found no significant changes in FKBP12.6-RyR2 binding either at subsaturating or saturating [F-FKBP] in sham versus HF rat myocytes ( Figure 8D ). 
Discussion
Here we resolved CaM binding to RyR2 versus other Z-line-binding partners and characterized CaM-RyR2 binding properties (K d and on/off rates) in permeabilized ventricular myocytes by 3 independent methods (Online Table  I ). RyR2
ADA/+ KI mice with disrupted CaM-RyR2 binding were used to determine that >90% of Z-line CaM is bound to RyR2. Functional consequences of reduced CaM binding to RyR2 were detected using Ca 2+ measurements in WT versus RyR2 ADA/+ KI myocytes, with CaM wash-out from WT myocytes, and arrhythmogenesis tests in mice. We also found CaM-RyR binding affinity to be reduced in HF myocytes. These results provide important new insights into understanding CaM-RyR2 interactions in normal and HF myocytes.
CaM-RyR2 Binding Properties in Myocytes
CaM, as a key regulator of RyR2 function, may be important in myocyte Ca 2+ homeostasis in HF, cardiac hypertrophy, and CPVT. But in situ CaM-RyR2 binding properties were previously unknown. Using 3 independent methods, we demonstrated that CaM binds to ]. [12] [13] [14] 23, 26, 42 The CaM-RyR2 binding affinity we measured in myocytes is higher than in cell lysates and SR vesicles. 17, 27 This could be because of differences in experimental conditions or subcellular fractionation effects. In SR vesicles, essential partners from the cellular environment may be lost, or post-translational modifications of RyR2 might occur (eg, phosphorylation or oxidation), which can alter CaM-RyR2 affinity. 23, 43 Using 3 methods, we measured similar CaM-RyR2 affinities that are consistent with CaM's physiological function. 13, 23 This supports that our K d measurements (10-20 nmol/L) are valid for the CaM-RyR2 binding affinity in the native cardiac myocyte environment.
According to our data, CaM-RyR2 has a relatively slow k off (≈0.2/min), meaning that the average dwell time for CaM on RyR2 is ≈5 minutes under resting conditions. In addition, high [Ca] 2+ i (500 nmol/L) strengthens CaM binding to RyR/Zlines and greatly slows CaM dissociation. 18, 34 Hence, increased CaM-RyR2 affinity during the Ca 2+ transient (<1 s) would further enhance CaM saturation at all RyR2 monomers in the physiological beat-to-beat situation. Furthermore, it was proposed that CaM can switch between 2 binding sites separated by ≈33Å on RyR1 during each cardiac cycle. 44, 45 The 2-site switch involves 2 sets of association and dissociation process, which seems unlikely to occur within the short systolic time, according to our measured kinetics. Taken together, these suggest that CaM is a resident RyR2-associated protein anchored at least to residues 3583 to 3603. This interpretation is consistent with a recent cryo-EM report placing apo-and Ca-CaM at the same location within the RyR2 map. 46 However, we cannot exclude the possibility of beat-to-beat RyR2 regulation by CaM because homozygous RyR2 ADA/ADA myocytes exhibit prolonged Ca 2+ transient and spark durations. That is consistent with the possible importance of resident CaM for RyR2 shutoff. 13 
Nearly All Z-Line-Bound CaM Is on RyR2
An important finding here is that >90% of the total Z-lineassociated CaM is bound to RyR2, that is, ≈1.2 μmol/L ( Figure 1E ). This is consistent with our FKBP12.6 B max measurements 22 and with the estimated concentration of RyR2 monomers in rat ventricular myocytes, 48 implying that there may be ≈70 nmol/L of non-RyR2 CaM-binding sites at the Z-line. Because the LTCC also binds CaM at the Z-line, and there are ≈32 RyR2 monomers per LTCC in rat myocytes, 48 LTCC would bind ≈40 nmol/L CaM, consistent with our release, but also exhibit profound HF, death within ≈2 weeks of birth, 70% reduction in RyR2 expression, and T-tubule disorganization. 13, 24 Remarkably, RyR2
ADA/+ mice have normal lifespan, myocyte ultrastructure, and RyR2 expression with no hypertrophy. 13 This is similar to KI mice carrying a CPVT1 mutation (RyR2-R2474S), 28, 50 where heterozygous mice survive without hypertrophy similar to WT, but the homozygous KI is lethal. Decreased CaM-RyR2 binding affinity has also been reported in CPVT1 KI mice under stress conditions known to be arrhythmogenic. 27 Thus, the RyR2 ADA/+ mice studied here resemble a CPVT1 model, and we also assessed abnormal SR Ca 2+ release and stress-induced arrhythmic events in these mice.
Baseline 28, 29 In particular, the bidirectional VT seen in RyR2
ADA/+ (but not WT mice) is clinically diagnostic for CPVT. 29 Although this RyR2 ADA mutation is not a known disease-linked mutation in humans, it causes a CPVT-like phenotype. There are also 2 recent CaM mutations that are associated with CPVT in patients, 30 and the CPVT phenotype may well result from effects of these mutant CaMs analogous to our RyR2 ADA/+ mouse results here. We cannot exclude the possibility that the ADA triple mutation alters RyR2 domain interactions, which might also contribute to the functional effects observed. However, the similarity between the RyR2 ADA/+ and simply depleting CaM from the WT RyR2 (Online Figure V) 
CaM-RyR2 Binding Affinity in HF Myocytes
Previous work in HF rabbit and canine models demonstrated reduced RyR2-bound CaM, based on coimmunoprecipitation and biochemical analysis, 25, 26 but total CaM expression was unaltered. 25 Here, we directly measured CaM and FKBP12.6 affinity for RyR2 in situ in HF myocytes. We found a 3-fold lower CaM affinity in HF myocytes, whereas FKBP12.6 affinity was unaltered. This quantitative information allows novel inferences. Assuming that free [CaM] in HF myocytes is 50 to 100 nmol/L, 34 the saturation of RyR2 monomers with CaM would be expected to drop from 70%-90% to 50%-70% in HF. This lower RyR2 saturation with CaM may have an analogous functional effect to those that we found in the RyR2 ADA/+ mice, where only 50% of RyR2 can bind CaM. The implication is that reduced CaM binding to RyR2 may contribute to the known increased SR Ca 2+ leak in HF 4, 25 and to the incidence of arrhythmias, which are responsible for 50% of HF deaths. 1 Furthermore, attenuated CaM-RyR2 association in HF could allow other intracellular CaM targets of lower affinity to be better activated, because RyR2 is a major CaM site in myocytes. 11 One such site is CaMKII, which is activated in HF and contributes to SR Ca 2+ leak and arrhythmogenesis by phosphorylation and activation of RyR2. 25 Thus, decreased CaMRyR2 association in HF may synergize with other regulatory pathways to exacerbate cardiac dysfunction and arrhythmias.
Overall, the HF-associated SR Ca 2+ leak is a complicated process involving several factors (eg, CaM, CaMKII, FKBP12.6, redox modification). Here, for the first time, we measured directly the in situ binding affinity of RyR2 for FKBP12.6 in HF myocytes, but found it to be unaltered versus control. We conclude that CaM binding to RyR2 may be an important physiological regulator of RyR2 gating in cardiac myocytes and that defects in this binding in HF or CPVT might constitute an important molecular mechanism of triggered arrhythmias suitable for therapeutic targeting.
